Portage Biotech Inc (PRTG) AI Stock Analysis

• Market Cap: $20.05M
• Dividend Yield: N/A
• Average Volume (3M): 35.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.02
• Revenue Growth: N/A
• EPS Growth: 48.91%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,278,622
• 10 Day Avg. Volume: 70,174
• 30 Day Avg. Volume: 35,124
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -131.01
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: ―

Portage Biotech Inc. exhibits significant financial weaknesses, such as no revenue and persistent losses, which heavily weigh down the overall score. Despite strong technical indicators suggesting bullish momentum, the poor valuation metrics and financial performance hinder the stock's attractiveness. The absence of earnings call data or notable corporate events leaves these factors out of consideration.

Portage Biotech Inc Business Overview & Revenue Model

Company Description

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

How the Company Makes Money

Portage Biotech Inc. generates revenue primarily through the development and commercialization of its proprietary cancer immunotherapy products. The company's revenue streams include licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies. These partnerships often involve milestone payments, royalties on sales, and joint development efforts that leverage Portage's innovative technologies. Additionally, the company may receive funding from grants and research collaborations that support the advancement of its therapeutic pipeline. Portage's focus on cutting-edge oncology solutions positions it to capitalize on the growing demand for effective cancer treatments, contributing to its financial performance.

Portage Biotech Inc Financial Statement Overview

Summary

Portage Biotech Inc. faces significant financial challenges, with no revenue generation, persistent losses, and negative cash flows. Although the company maintains low leverage, its declining equity and asset base raise concerns about long-term sustainability. The financial outlook remains bleak without strategic improvements or revenue generation.

Income Statement

Portage Biotech Inc. has reported zero revenue over the periods, indicating no sales activity. The company consistently incurs high net losses, resulting in negative net profit margins. EBIT and EBITDA margins are also negative, reflecting operational challenges in generating profits.

Balance Sheet

The company's debt-to-equity ratio is low, indicating minimal leverage. However, the declining stockholders' equity and total assets suggest weakening financial stability. The equity ratio remains positive but is trending downward, highlighting potential risks in asset management.

Cash Flow

Operating cash flow remains negative, highlighting inefficiencies in generating cash from core operations. Free cash flow is negative, showing continued cash outflows. There is no observable growth in free cash flow, raising concerns about liquidity.

Breakdown	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-54.00K	-1.00K	0.00	0.00	0.00
EBITDA	-18.20M	-15.78M	-15.59M	-14.19M	-5.95M
Net Income	-75.34M	-104.61M	-16.87M	-15.83M	-5.33M
Balance Sheet
Total Assets	7.78M	99.13M	194.66M	174.86M	173.17M
Cash, Cash Equivalents and Short-Term Investments	5.03M	10.54M	23.35M	2.77M	3.22M
Total Debt	47.00K	0.00	0.00	150.00K	3.66M
Total Liabilities	4.45M	23.73M	29.23M	27.26M	27.53M
Stockholders Equity	4.02M	76.05M	121.20M	101.45M	96.53M
Cash Flow
Free Cash Flow	-14.30M	-12.08M	-6.76M	-3.28M	-3.71M
Operating Cash Flow	-14.30M	-12.07M	-6.76M	-4.28M	-3.71M
Investing Cash Flow	2.81M	-617.00K	0.00	-860.00K	0.00
Financing Cash Flow	5.97M	-117.00K	27.35M	4.76M	700.00K

Portage Biotech Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTG, the sentiment is Positive. The current price of 8.9 is above the 20-day moving average (MA) of 7.03, above the 50-day MA of 6.57, and above the 200-day MA of 5.93, indicating a bullish trend. The MACD of 0.77 indicates Negative momentum. The RSI at 63.95 is Neutral, neither overbought nor oversold. The STOCH value of 70.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRTG.

Portage Biotech Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	57 Neutral	£5.17B	4.93	-44.55%	2.32%	28.89%	-10.08%
BMRA	49 Neutral	$7.61M	―	-72.70%	―	5.05%	26.13%
ADXN	49 Neutral	$13.06M	0.65	-162.42%	―	-82.24%	―
DWTX	49 Neutral	$9.27M	―	-494.11%	―	―	-219.97%
EKSO	48 Neutral	$7.94M	―	-96.44%	―	-19.32%	44.73%
PRTG	48 Neutral	$20.05M	―	-194.84%	―	―	48.91%
ABVC	43 Neutral	$49.93M	―	-39.93%	―	1904.43%	93.72%